Acute cardiac care & resuscitation

A retrospective ‘target trial emulation’ comparing amiodarone and lidocaine for adult out-of-hospital cardiac arrest resuscitation

ResuscitationPublished retrospective 'target trial emulation'

Main finding · Prehospital ROSCResult — go to the resultAdjusted odds ratio 1.29 CI 1.16–1.44

Authors' conclusion

Our 'target trial emulation' suggested that lidocaine was associated with greater odds of prehospital ROSC in comparison to amiodarone when administered during resuscitation from shock refractory or recurrent VF/VT.

Study context

Population
Adult, non-traumatic out-of-hospital cardiac arrest (OHCA) patients in the ESO Data Collaborative 2018–2023 datasets who experienced OHCA prior to EMS arrival, presented with a shockable rhythm, and received amiodarone or lidocaine during resuscitationpatients from 1,707 EMS agencies eligible for analysis, 2,976 matched pairs
Participants
23,263 participants
Exposure
Lidocaine vs amiodarone during resuscitation
  • Lidocainen = 2,979
  • Amiodaronen = 20,284reference
Outcome
Prehospital return of spontaneous circulation (ROSC)
Methodological detailspropensity score matching (PSM)
  • Propensity score matching (PSM)

Main finding

As reported in the abstract

Adjusted odds ratio

1.29

CI 1.16–1.44

By group

Lidocaine

36.0

%

Amiodarone

30.4%

Lidocainevs amiodarone
aOR 1.29 (CI 1.16–1.44)

Observational data: associations, not effects.

Secondary outcomes

OutcomeLidocaineAmiodaroneOR (CI)
Survival to hospital dischargen = 538 pairs35.1 %25.7%1.54 (1.19–2.00)
OutcomeLidocaineAmiodaroneP value
Number of post-drug defibrillationsFewer with lidocaine; n = 2,976 pairs · median2 (range 0–4)2 (range 0–6)P < 0.01
Mean3.33.9

Original publication

A retrospective ‘target trial emulation’ comparing amiodarone and lidocaine for adult out-of-hospital cardiac arrest resuscitation. Resuscitation. Published 23 January 2025. doi:10.1016/j.resuscitation.2025.110515

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.